REVIEW ARTICLE
Free to Read
The evolution of adjuvant/neoadjuvant trials for resectable localized sarcoma
Mai-Kim Gervais MD,
Dario Callegaro MD,
Alessandro Gronchi MD,
Mai-Kim Gervais MD
Division of Surgical Oncology, Department of Surgery, Maisonneuve-Rosemont Hospital, Universite de Montreal, Montreal, Quebec, Canada
Search for more papers by this authorDario Callegaro MD
Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Search for more papers by this authorCorresponding Author
Alessandro Gronchi MD
Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Correspondence Alessandro Gronchi, MD, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Email: [email protected]
Search for more papers by this authorMai-Kim Gervais MD,
Dario Callegaro MD,
Alessandro Gronchi MD,
Mai-Kim Gervais MD
Division of Surgical Oncology, Department of Surgery, Maisonneuve-Rosemont Hospital, Universite de Montreal, Montreal, Quebec, Canada
Search for more papers by this authorDario Callegaro MD
Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Search for more papers by this authorCorresponding Author
Alessandro Gronchi MD
Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Correspondence Alessandro Gronchi, MD, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Email: [email protected]
Search for more papers by this authorAbstract
Soft-tissue sarcomas are rare tumors arising from mesenchymal tissues. As a heterogeneous group comprising more than 50 types, the development of clinical trials remains challenging. Decision-making for neoadjuvant or adjuvant chemotherapy and radiation therapy is based on the available evidence of contemporary trials and multidisciplinary clinical judgment.
CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.
Open Research
DATA AVAILABILITY STATEMENT
Data are available from the corresponding author upon reasonable request.
REFERENCES
- 1Mastrangelo G, Coindre JM, Ducimetière F, et al. Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions. Cancer. 2012; 118: 5339-5348.
- 2Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66: 271-289.
- 3 American Cancer Society. 2021. https://www.cancer.org/cancer/soft-tissue-sarcoma/about/key-statistics.html. Accessed August 31, 2021.
- 4Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand Suppl. 1994; 259: 1-31.
- 5 Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). Research Data (2014–1018). National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch; 2015.
- 6Guadagnolo BA, Zagars GK, Ballo MT, Strom SS, Pollock RE, Benjamin RS. Mortality after cure of soft-tissue sarcoma treated with conservation surgery and radiotherapy. Cancer. 2008; 113: 411-418.
- 7Cable MG, Randall RL. Extremity soft tissue sarcoma: tailoring resection to histologic subtype. Surg Oncol Clin N Am. 2016; 25: 677-695.
- 8Gladdy RA, Gupta A, Catton CN. Retroperitoneal sarcoma: fact, opinion, and controversy. Surg Oncol Clin N Am. 2016; 25: 697-711.
- 9Gronchi A, Strauss DC, Miceli R, et al. Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative RPS Working Group. Ann Surg. 2016; 263: 1002-1009.
- 10Jacobs AJ, Michels R, Stein J, Levin AS. Improvement in overall survival from extremity soft tissue sarcoma over twenty years. Sarcoma. 2015; 2015:279601.
- 11Gronchi A, Miceli R, Colombo C, et al. Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution. Ann Oncol. 2011; 22: 1675-1681.
- 12Bonvalot S, Gronchi A, Le Péchoux C, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020; 21(10): 1366-1377.
- 13Rosenberg SA. Adjuvant chemotherapy for adult patients with soft-tissue sarcomas. Important Adv Oncol. 1985: 273-294.
- 14Bramwell VHC. Adjuvant chemotherapy for adult soft-tissue sarcoma: is there a standard of care? J Clin Oncol. 2001; 19: 1235-1237.
- 15Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993; 11: 1276-1285.
- 16Tierney JF, Mosseri V, Stewart LA, Souhami RL, Parmar MK. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomized clinical trials. Br J Cancer. 1995; 72: 469-475.
- 17 Sarcoma Meta-Analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997; 350: 1647-1654.
- 18Gortzak E, Azzarelli A, Buesa J, et al. Randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer. 2001; 37(9): 1096-1103.
- 19Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008; 113: 573-581.
- 20Woll PJ, Reichardt P, Le Cesne A, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012; 13: 1045-1054.
- 21Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001; 19: 1238-1247.
- 22Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the adjuvant therapy of soft tissuesarcomas. Oncology. 2003; 65(suppl 2): 80-84.
- 23Gronchi A, Frustaci S, Mercuri M, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012; 30: 850-856.
- 24Gronchi A, Stacchiotti S, Verderio P, et al. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. Ann Oncol. 2016; 27(12): 2283-2288.
- 25Petrioli R, Coratti A, Correale P, et al. Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma. Am J Clin Oncol. 2003; 25: 468-473.
- 26Casali PG. Adjuvant chemotherapy for soft tissue sarcoma. Am Soc Clin Oncol Educ Book. 2015: e629-e633.
- 27Pasquali S, Palmerini E, Quagliulo V, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: a Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. Cancer. Published online October 13, 2021. doi:10.1002/cncr.33895
- 28Brodowicz T, Schwameis E, Widder J, et al. Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: a prospective randomized feasibility trial. Sarcoma. 2000; 4: 151-160.
- 29D'Adamo DR. Appraising the current role of chemotherapy for the treatment of sarcoma. Semin Oncol. 2011; 38: S19-S29.
- 30D'Adamo DR. Is adjuvant chemotherapy useful for soft-tissue sarcomas? Lancet Oncol. 2012; 13: 968-970.
- 31Pasquali S, Pizzamiglio S, Touati N, et al. EORTC—Soft Tissue and Bone Sarcoma Group. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer. 2019; 109: 51-60.
- 32Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017; 18(6): 812-822.
- 33Gronchi A, Palmerini E, Quagliuolo V, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol. 2020; 38(19): 2178-2186.
- 34NCCN clinical practice guidelines in oncology. Soft tissue sarcoma. Version 2. 2021. https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed August 31, 2021.
- 35Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas:ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(11): 1348-1365.
- 36Kraybill WG, Harris J, Spiro IJ, et al. Phase II study of neoadjuvant hemotherapy and radiation therapy in the management of high-risk, high grade, soft tissue sarcomas of the extremities and body wall: radiation therapy oncology group trial 9514. J Clin Oncol. 2006; 24: 619-625.
- 37Gronchi A, De Paoli A, Dani C, et al. Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. Eur J Cancer. 2014; 50(4): 784-792.
- 38Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996; 14: 859-868.
- 39Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998; 16: 197-203.
- 40O'sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002; 359: 2235-2241.
- 41Davis AM, O'sullivan B, Turcotte R, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005; 75: 48-53.
- 42Pawlik TM, Pisters PW, Mikula L, et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol. 2006; 13(4): 508-517.
- 43Sindelar WF, Kinsella TJ, Chen PW, et al. intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial. Arch Surg. 1993; 128: 402-410.
- 44Roeder F, Ulrich A, Habl G, et al. Clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma: interim analysis. BMC Cancer. 2014; 14: 617.
- 45Smith MJ, Ridgway PF, Catton CN, et al. Combined management of retroperitoneal sarcoma with dose intensification radiotherapy and resection: long-term results of a prospective trial. Radiother Oncol. 2014; 110(1): 165-171.
- 46Haas RL, Miah AB, LePechoux C, et al. Preoperative radiotherapy for extremity soft tissue sarcoma past, present and future perspectives on dose fractionation regimens and combined modality strategies. Radiother Oncol. 2016; 119(1): 14-21.
- 47Palassini E, Ferrari S, Verderio P, et al. Feasibility of preoperative chemotherapy with or without radiation therapy in localized soft tissue sarcomas of limbs and superficial trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas randomized clinical trial: three versus five cycles of full-dose epirubicin plus ifosfamide. J Clin Oncol. 2015; 1(33): 3628-3634.
- 48Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982; 196: 305-315.
- 49Larrier NA, Czito BG, Kisrsh DG. Radiation therapy fort soft-tissue sarcoma: indications and controversies for neoadjuvant therapy, adjuvant therapy, intraoperative radiation therapy, and brachytherapy. Surg Oncol Clin N Am. 2016; 25: 841-860.
- 50Pisters PW, Ballo MT, Fenstermacher MJ, et al. Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. J Clin Oncol. 2003; 21(16): 3092-3097.
- 51Wang D, Zhang Q, Eisenberg BL, et al. Significant reduction of late toxicities in patients with extremity sarcoma treated with image-guided radiation therapy to a reduced target volume: results of radiation therapy oncology group RTOG-0630 trial. J Clin Oncol. 2015; 33: 2231-2238.
- 52O'Sullivan B, Griffin AM, Dickie CI, et al. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. Cancer. 2013; 119(10): 1878-1884.
- 53Röper B, Heinrich C, Kehl V, et al. Study of preoperative radiotherapy for sarcomas of the extremities with intensity-modulation, image-guidance and small safety-margins (PREMISS). BMC Cancer. 2015; 16(15): 904.
10.1186/s12885-015-1633-y Google Scholar
- 54Fiore M, Ford S, Callegaro D, et al. Adequate local control in high risk soft tissue sarcoma of the extremity treated with surgery alone at a reference centre: should radiotherapy still be a standard? Ann Surg Oncol. 2018; 25(6): 1536-1543.
- 55Robertson JM, Sondak VK, Weiss SA, Sussman JJ, Chang AE, Lawrence TS. Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys. 1995; 31(1): 87-92.
- 56Jones JJ, Catton CN, O'Sullivan B, et al. Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma. Ann Surg Oncol. 2002; 9(4): 346-354.
- 57Pisters P. Surgery with or without radiation therapy in treating patients with primary soft tissue sarcoma of the retroperitoneum or pelvis. 2004. Clinicaltrials.gov NCT00091351
- 58Callegaro D, Raut C, Ajayi Taiwo A, et al. Pre-operative radiotherapy in patients with primary retroperitoneal sarcoma. Trial (STRASS) vs off-trial (STREXIT) results. Annual Virtual Meeting Connective Tissue Oncology Society (CTOS); November 18–21, 2020.
- 59Surgery with or without neoadjuvant chemotherapy in high risk retroperitoneal sarcoma (STRASS2). 2019. Clinicaltrials.gov NCT04031677.
- 60Martin-Broto J, Hindi N, Lopez-Pousa A, et al. Assessment of safety and efficacy of combined trabectedin and low-dose radiotherapy for patients with metastatic soft-tissue sarcomas: a nonrandomized phase 1/2 clinical trial. JAMA Oncol. 2020; 6(4): 535-541.
- 61Tseng WW, Pasquali S, Hu JS, Menendez LR, Gronchi A. Staging systems and nomograms in soft tissue sarcoma: outcome prediction by categorization or personalization? Chin Clin Oncol. 2019; 8(S1–S12): 12.
- 62Tap WD, Wagner AJ, Schöffski P, et al. Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the announce randomized clinical trial. JAMA. 2020; 323(13): 1266-1276.
- 63Seddon B, Strauss SJ, Whelan J, et al. Articles gemcitabine and docetaxel versus doxorubicin as rst-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017; 18(10): 1397-1410.
- 64Ayodele O, Abdul Rasak AR. Immunotherapy in soft-tissue sarcoma. Current Oncol. 2020; 27: 17-23.
- 65D'angelo SP, Shoushtari AN, Agaram NP, et al. Prevalence of tumour-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015; 46: 357-365.
- 66Klemen ND, Kelly CM, Bartlett EK. The emerging role of immunotherapy for the treatment of sarcoma. J Surg Oncol. 2021; 123: 730-738.
- 67Tran E, Ahmadzadeh M, Lu YC, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015; 350(6266): 1387-1390.
- 68Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017; 9(1): 34.
- 69Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (sarc028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017; 18: 1493-1501.
- 70Burgess MA, Bolejack V, Schuetze S, et al. Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): final results of sarc028 expansion cohorts. J Clin Oncol. 2019; 37(15_suppl):11015–11015. doi:10.1200/JCO.2019.37.15_suppl.11015
- 71Maki RG, Jungbluth AA, Gnjatic S, et al. A pilot study of anti CTLA-4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma. 2013; 2013:168145.
- 72D'angelo SP, Mahoney MR, Van Tine BA, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018; 19: 416-446.
- 73Chen JL, Mahoney MR, George S, et al. A multicenter phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): results of expansion cohorts. J Clin Oncol. 2020; 38:11511.
- 74Somaiah N, Conley AP, Lin HY, et al. A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas. J Clin Oncol. 2020; 38:11509.
10.1200/JCO.2020.38.15_suppl.11509 Google Scholar
- 75Pollack S, Redman MW, Baker KK, et al. Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial. JAMA Oncol. 2020; 6(11): 1778–1782. doi:10.1200/JCO.2019.37.15_suppl.11009
- 76Toulmonde M, Penel N, Adam J, et al. Use of PD-1 Targeting, macrophage infiltration, and IDO pathway activation in sarcomas. JAMA Oncol. 2018; 4(1): 93-95.
- 77 A randomized trial of pembrolizumab and radiotherapy versus radiotherapy in high-risk soft-tissue sarcoma of the extremity (SU2C-SARC032). 2017. Clinicaltrials.gov NCT03092323
- 78 A study of talimogene laherparepvec (T-VEC) in combination with pembrolizumab in patients with metastatic and/or locally advanced sarcoma. 2017. Clinicaltrials.gov NCT03069378.
- 79Roland CL, Keung EZY, Lazar AJ, et al. Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). J Clin Oncol. 2020; 38(15_suppl):11505.
